Manidipine

Manidipine, a Ca(2+)-channel blocker, at concentrations that lower elevated blood pressure, modulates the transcription rates of cytokine genes in the mesangial cells of humans that had been stimulated with platelet-derived growth factor BB isomer. ^[1] Manidipine inhibits the ET-1-induced [Ca2+]i increase by reducing both the transient and sustained Ca2+ increments in A7r5 cells and glomerular mesangial cells (MCs). Manidipine (10(-5) mol/L) potentiates ET-1-induced c-fos and c-jun expression in A7r5 cells. Manidipine is a potent inhibitor for ET-1-induced [Ca2+]i signaling and that Manidipine has multiple effects on ET-1-induced signaling, including potentiating the immediate-early gene response. ^[2]

Manidipine reduces systolic blood pressure with a slight sympathetic reflex increase in heart rate, and increases plasma nitrite/nitrates in perfused rat heart from ischemia-reperfusion damage. Manidipine combined with Simvastatin reduces creatine kinase, lactate dehydrogenase and tumor necrosis factor-alpha, and enhancement of 6-keto-PGF(1alpha) during reperfusion. ^[3] Manidipine hydrochloride prevents isoproterenol-induced left ventricular hypertrophy and expression of mRNA of ANP, collagen types I and type III, and fibronectin in rats with isoproterenol-induced cardiac hypertrophy. ^[4] Manidipine HCl increases renal blood flow (RBF) by dilating the afferent arterioles and improves glomerular hypertension by dilating the efferent arterioles in hypertensive rats. ^[5]